Globalpharma, the leading pharmaceutical manufacturer in the UAE and a fully owned subsidiary of Dubai Investments PJSC, revealed its ambitious plans for 2025, highlighting the launch of 25 new and innovative products across key therapeutic areas.
These areas encompass diabetes, cardiovascular health, gastroenterology, and orthopaedics.
This significant milestone demonstrates Globalpharma’s dedication to providing high-quality, accessible medications that meet the evolving healthcare needs of the region, according to the company.
“Globalpharma’s growth and innovation are perfectly aligned with Dubai Investments’ vision of driving transformation in key industries,” stated Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries & Masharie, and Board Director of Globalpharma.
“As the pharmaceutical sector continues to expand, the Group is strategically positioning Globalpharma to seize emerging opportunities,” he added.
Al Raqbani emphasised that the goal is not only to contribute to the region’s healthcare ecosystem but also to position Dubai Investments as a major player in the global pharmaceutical industry.
“Through innovation, partnerships, and a focus on patient-centric solutions, we are confident that Globalpharma will continue to strengthen its presence and make a significant impact,” he remarked.
As part of its broader expansion strategy, Globalpharma is enhancing its distribution network and establishing new partnerships.
Furthermore, the company stated it is refining its market entry strategies to cater to the unique needs of regional markets, consolidating its position in key territories while exploring new prospects.
“Our strategic priorities for 2025 centre on innovation, accessibility, and partnerships,” said Basem Albarahmeh, General Manager of Globalpharma.
